Minerva Surgical, Inc. is a medical technology company. The company is headquartered in Santa Clara, California and currently employs 174 full-time employees. The company went IPO on 2021-10-22. The firm designs, manufactures, distributes, and commercializes a suite of products that offer effective alternatives to hysterectomy, with a focus on diagnosing and treating the underlying causes of Abnormal Uterine Bleeding (AUB). Its solutions are designed for use across a variety of care settings and focused on improving clinical outcomes and preserve uterine anatomy. The company delivers devices that treat the root causes of AUB in both the normal and irregular shaped uterus. The firm's products include Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Operative Hysteroscopy System (Symphion), Resectr Tissue Resection Device (Resectr), and HERizon Disposable Hysteroscope. Its Minerva EAS includes PlasmaSense Technology, which monitors uterine cavity. The company also provides HERizon Hysto-Kit, which supports in-office hysteroscopy.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for UTRS. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: UTRS is a Buy candidate.
UTRS stock price ended at $0 on 水曜日, after rising NaN%
On the latest trading day May 20, 2026, the stock price of UTRS rose by NaN%, climbing from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. Notably, trading volume dropped by 29.0K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 30.0K shares were traded, equating to a market value of approximately --.